keyword
MENU ▼
Read by QxMD icon Read
search

Inhaled corticosteroids and asthma

keyword
https://www.readbyqxmd.com/read/29792288/tralokinumab-for-severe-uncontrolled-asthma-stratos-1-and-stratos-2-two-randomised-double-blind-placebo-controlled-phase-3-clinical-trials
#1
Reynold A Panettieri, Ulf Sjöbring, AnnaMaria Péterffy, Peter Wessman, Karin Bowen, Edward Piper, Gene Colice, Christopher E Brightling
BACKGROUND: Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the efficacy and safety of tralokinumab in this population. METHODS: STRATOS 1 and STRATOS 2 were randomised, double-blind, parallel-group, placebo-controlled, phase 3 clinical trials that enrolled participants aged 12-75 years with severe asthma that was inadequately controlled despite use of inhaled corticosteroids (≥500 μg per day fluticasone or equivalent) and a long-acting β2 agonist (but not oral corticosteroids)...
May 18, 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29781332/a-novel-phenolic-propanediamine-moiety-based-lung-targeting-therapy-for-asthma
#2
Jianbo Li, Yang Yang, Didi Wan, Youmei Peng, Jinjie Zhang
Asthma is one of the most prevalent chronic inflammatory diseases of lung. Current asthma therapy using inhaled corticosteroid often results in undesired treatment outcome due to poor compliance and drugs' lack of tissue specificity. N,N,N'-trimethyl-N'-(2-hydroxyl-3-methyl-5-123 Iiodobenzyl)-1,3-propanediamine (HIPD), a phenolic propanediamine derivative, has been used as an imaging agent for localized pulmonary diseases. Inspired by this, N,N,N'-trimethyl-N'-(4-hydroxyl-benzyl)-1,3-propanediamine (TPD), a new HIPD analog, was proposed as a lung-targeting ligand and covalently conjugated to an anti-inflammatory compound Rhein for asthma therapy...
November 2018: Drug Delivery
https://www.readbyqxmd.com/read/29780238/update-on-new-biologics-for-intractable-eosinophilic-asthma-impact-of-reslizumab
#3
REVIEW
Jagdeep Sahota, Douglas S Robinson
A small percentage of patients with asthma have uncontrolled symptoms and frequent exacerbations, despite treatment with inhaled corticosteroids and other agents. It has become clear that different subtypes of this severe, treatment-resistant group exist due to different mechanisms of the disease. All such patients require detailed assessment in specialist centers to characterize the disease and assess treatment adherence. Recently, monoclonal antibodies have become available, which target specific pathways that may contribute to persistent inflammation and asthma exacerbations...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29780119/a-rare-case-of-isolated-chronic-cough-caused-by-pulmonary-lymphangitic-carcinomatosis-as-a-primary-manifestation-of-rectum-carcinoma
#4
Minami Okayama, Yoshihiro Kanemitsu, Tetsuya Oguri, Takamitsu Asano, Satoshi Fukuda, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio Niimi
A 36-year old man was referred to our hospital due to isolated chronic cough that was refractory to anti-asthma medications, including inhaled corticosteroids/long-acting β2 agonists. Chest X-ray showed diffuse nodular and enhanced vascular shadows with Kerley lines in both lungs. A blood analysis showed elevated serum CEA and CA19-9 levels. A transbronchial biopsy revealed well to moderately differentiated adenocarcinoma, the origin of which was immunohistochemically suspected to be the gastrointestinal tract...
May 18, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29765200/efficacy-and-safety-of-the-crth2-antagonist-azd1981-as-add-on-therapy-to-inhaled-corticosteroids-and-long-acting-%C3%AE-2-agonists-in-patients-with-atopic-asthma
#5
Eric D Bateman, Christopher O'Brien, Paul Rugman, Sally Luke, Stefan Ivanov, Mohib Uddin
Objectives: To evaluate the efficacy and safety of AZD1981, a potent, specific antagonist of the CRTh2 receptor, as add-on therapy to inhaled corticosteroids (ICS) and long-acting β2 -agonists (LABA), in patients with persistent asthma with an allergic component. Patients and methods: In this placebo-controlled, parallel-group Phase IIb study, patients with persistent atopic asthma on ICS and LABA were randomized to receive 12 weeks of treatment with placebo or AZD1981 (80 mg daily, 200 mg daily, and 10 mg, 40 mg, 100 mg, or 400 mg twice daily [BID])...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29762633/using-a-mixture-of-bivariate-regression-model-to-explore-heterogeneity-of-effects-of-use-of-inhaled-corticosteroids-on-gestational-age-and-birthweight-among-pregnant-women-with-asthma
#6
Mariia Samoilenko, Lucie Blais, Isabelle Boucoiran, Geneviève Lefebvre
Asthma is a heterogeneous disease, and responses to asthma medications vary noticeably among patients. A substantively oriented objective of this study was to explore the potential heterogeneous effects of maternal inhaled corticosteroids (ICS) exposure on gestational age (GA) at delivery and birthweight (BW) using a cohort of 6,197 pregnancies from women with asthma (Quebec, Canada, 1998-2008). A methodologically oriented objective was to comprehensively describe the application of a Bayesian two-component mixture of bivariate regressions to address this issue and estimate the effects of ICS on GA and BW jointly...
May 14, 2018: American Journal of Epidemiology
https://www.readbyqxmd.com/read/29759659/the-global-development-and-clinical-efficacy-of-sublingual-tablet-immunotherapy-for-allergic-diseases
#7
REVIEW
Hendrik Nolte, Jennifer Maloney
Allergy immunotherapy (AIT) is a treatment option for respiratory allergy that is complementary to pharmacotherapy, with a distinct mechanism of action. Alternative methods to subcutaneous administration of AIT that enable patients to safely self-administer AIT is considered an unmet clinical need. The sublingual immunotherapy tablet (SLIT-tablet) is an orally disintegrating pharmaceutical formulation (oral lyophilisate) containing standardized allergens. SLIT-tablets have been developed for sublingual immunotherapy (SLIT) of cedar-pollen, grass-pollen, ragweed-pollen, tree-pollen, and house dust mite allergies...
May 12, 2018: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/29755346/a-multicenter-randomized-double-blind-placebo-controlled-study-of-the-effects-of-loki-zupa-in-patients-with-chronic-asthma
#8
Yubao Lv, Ying Wei, Muhammadjan Abduwaki, Tohti Jurat, Fengsen Li, Huaizhen Wang, Yuhua Wu, Zheng Li, Bo Liu, Hongjun Yin, Yuxue Cao, Mammat Nurahmat, Zihui Tang, Jingcheng Dong
The purpose of this study was to evaluate the efficacy and safety of Uyghur medical formula Loki zupa in patients with chronic asthma. Adult patients with chronic asthma randomly received placebo or Loki zupa as add-on to inhaled corticosteroids (ICS) maintenance treatment. Loki zupa or mimics was administered orally 10 ml per time, three times a day for 8 weeks. The primary endpoints were asthma control test (ACT) score and peak expiratory flow (PEF). The secondary endpoints were acute exacerbation rate, lung function, night waking days, and symptom-free days in the near 2 weeks, Asthma Quality of Life Questionnaire (AQLQ) score and some inflammatory cytokines in peripheral blood...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29754592/general-practitioners-views-on-the-influence-of-cost-on-the-prescribing-of-asthma-preventer-medicines-a-qualitative-study
#9
Jacqueline Tudball, Helen K Reddel, Tracey-Lea Laba, Stephen Jan, Anthony Flynn, Michele Goldman, Kirsty Lembke, Elizabeth Roughead, Guy B Marks, Nick Zwar
Objective Out-of-pocket costs strongly affect patient adherence with medicines. For asthma, guidelines recommend that most patients should be prescribed regular low-dose inhaled corticosteroids (ICS) alone, but in Australia most are prescribed combination ICS-long-acting β2-agonists (LABA), which cost more to patients and government. The present qualitative study among general practitioners (GPs) explored the acceptability, and likely effect on prescribing, of lower patient copayments for ICS alone. Methods Semistructured telephone interviews were conducted with 15 GPs from the greater Sydney area; the interviews were transcribed and thematically analysed...
May 14, 2018: Australian Health Review: a Publication of the Australian Hospital Association
https://www.readbyqxmd.com/read/29754324/cost-utility-analysis-of-an-intervention-designed-to-reduce-the-critical-handling-error-of-insufficient-inspiratory-effort
#10
Rebecca Forster, Aran Ratcliffe, Megan Lewis, Amy Crossley, Julio López Bastida, William C N Dunlop
OBJECTIVES: Up to 70-80% of patients use inhalers incorrectly. Dry-powder inhalers (DPIs) require forceful inhalation for optimal delivery, and approximately 40% of Global Initiative for Asthma (GINA)-defined Step-3+ patients inhale corticosteroid and long-acting beta-agonist through DPIs. The CRITIKAL study (Price et al. in J Allergy Clin Immunol Pract 5:1071-e9-1081-e9, 2017) found a statistically significant association between 'insufficient inspiratory effort' error and increased risk of uncontrolled asthma and hospitalisation-requiring exacerbations...
May 12, 2018: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/29748063/-is-reduction-of-tobacco-consumption-associated-with-reduced-risk-of-cardiovascular-and-pulmonary-mortality-and-morbidity
#11
REVIEW
M Underner, G Peiffer, J Perriot, G Harika-Germaneau, N Jaafari
INTRODUCTION: Smokers without an intention to completely quit smoking often try to reduce their daily tobacco consumption. However, smoking reduction is not associated with reduced risk of all-cause mortality. The aim of this systematic literature review of data was to expose relations between reduction of daily tobacco consumption and a potential decrease in the risks of cardiovascular and pulmonary mortality and morbidity. METHOD: Medline, on the period 1980-2018 with the following keywords: "smoking reduction", "harm reduction", "mortality", "morbidity", "cardiovascular disease* ", myocardial infarction", "coronar* ", "stroke", "lung cancer", "COPD", "chronic obstructive pulmonary disease", "asthma", "pulmonary disease* " and "respiratory disease" limits "title/abstract"; the selected languages were English or French...
May 7, 2018: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/29747656/maternal-drug-use-and-the-risk-of-anorectal-malformations-systematic-review-and-meta-analysis
#12
REVIEW
Nadine Zwink, Ekkehart Jenetzky
BACKGROUND: Origin of anorectal malformations (ARM) are considered multifactorial. Several genetic and non-genetic risk factors are discussed in literature. Maternal periconceptional medical drug use as possible risk factor, however, has not been reviewed systematically. METHODS: Studies published between 1977 and April 2017 were reviewed through systematic search in PubMed, ISI Web of Knowledge and Scopus databases. Furthermore, related and cross-referencing publications were reviewed...
May 10, 2018: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/29743961/asthma-control-and-asthma-medication-use-among-swedish-elite-endurance-athletes
#13
Hampus Persson, Anne Lindberg, Nikolai Stenfors
Background: Asthma is common in elite athletes. In this study, we examined the use of asthma medication and asthma control in endurance athletes in Sweden and compared the findings with those in a reference group of patients with asthma. Methods: The Asthma Control Test (ACT) and a questionnaire on asthma, respiratory symptoms, and medication use were posted to endurance athletes ( n =711) and the reference group of patients with asthma ( n =1026). Four hundred and sixty-nine athletes (66%) responded, of whom 141 (20%) reported physician-diagnosed asthma...
2018: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
https://www.readbyqxmd.com/read/29741897/novel-pyrrolidine-derivatives-of-budesonide-as-long-acting-inhaled-corticosteroids-for-the-treatment-of-pulmonary-inflammatory-diseases
#14
Eleonora Ghidini, Gessica Marchini, Anna Maria Capelli, Chiara Carnini, Valentina Cenacchi, Alessandro Fioni, Fabrizio Facchinetti, Fabio Rancati
Inhaled corticosteroids (ICS) represent the first line therapy for the treatment of asthma and are also extensively utilized in chronic obstructive pulmonary disease. Our goal was to develop a new ICS with a basic group which can allow solid state feature modulation, achieving at the same time high local antiinflammatory effect and low systemic exposure. Through a rational drug design approach a new series of a pyrrolidine derivatives of budesonide was identified. Within the series, several compounds showed nanomolar binding affinity (Ki) with GR that mostly correlated with the effect in inducing GR nuclear translocation in CHO cells and anti-inflammatory effects in macrophagic cell lines...
May 9, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29735492/asthmatic-adult-with-marked-blood-eosinophilia-is-it-truly-asthma
#15
Shera Tan, Angela Takano, Aloysius Ho, Keng Leong Tan
A middle-aged woman presented with symptoms suggestive of allergic asthma but with markedly elevated peripheral eosinophilia. She did not respond to inhaled corticosteroids, thereby prompting further investigations. Chest radiograph was normal. CT of the chest revealed bi-apical ground glass opacities. Bronchoalveolar lavage revealed predominantly eosinophilic yield. Autoimmune screen was negative. Bone marrow biopsy showed a normocellular marrow with increased eosinophils. A diagnosis of chronic eosinophilic pneumonia (CEP) was made after exclusion of other causes of eosinophilia...
May 7, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29733738/case-study-a-combination-of-mepolizumab-and-omaluzimab-injections-for-severe-asthma
#16
Rejmon Dedaj, Lindie Unsel
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. INTRODUCTION: Patients with severe persistent asthma account for a large proportion of asthma morbidity and health care expenditures. In this case report we describe the use of a combination of omalizumab and mepolizumab in severe asthma with elevated IgE levels and eosinophilic phenotype. CASE STUDY: We are treating a 55 year old woman with severe persistent eosinophilic asthma and elevated IgE levels...
May 7, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29731926/practical-approach-to-lung-health-experience-from-the-republic-of-macedonia
#17
Biljana Ilievska-Poposka, Maja Zakoska, Stefan Talevski
BACKGROUND: Among the adults and children aged 5 yrs who attend PHC settings, 20-30% seeks to care for respiratory symptoms. Over 80-90% of the respiratory patients suffer from acute respiratory infections (ARI), followed by chronic obstructive pulmonary diseases (COPD), asthma, and less frequently with pneumonia and tuberculosis (TB). To improve the quality of care in patients who seek assistance for respiratory symptoms in PHC settings and the efficiency of respiratory service delivery within healthcare systems, WHO has designated several initiatives among which one is PAL (Practical Approach to Lung Health)...
April 15, 2018: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29725983/liberty-asthma-quest-phase-3-randomized-double-blind-placebo-controlled-parallel-group-study-to-evaluate-dupilumab-efficacy-safety-in-patients-with-uncontrolled-moderate-to-severe-asthma
#18
William W Busse, Jorge F Maspero, Klaus F Rabe, Alberto Papi, Sally E Wenzel, Linda B Ford, Ian D Pavord, Bingzhi Zhang, Heribert Staudinger, Gianluca Pirozzi, Nikhil Amin, Bolanle Akinlade, Laurent Eckert, Jingdong Chao, Neil M H Graham, Ariel Teper
INTRODUCTION: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis. Following positive phase 2 results in asthma, the phase 3 Liberty Asthma QUEST trial was initiated to provide further evidence for dupilumab efficacy and safety in patients with uncontrolled, moderate-to-severe asthma...
May 3, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29724395/asthma-control-in-adults-in-the-middle-east-and-north-africa-results-from-the-esmaa-study
#19
Hesham Tarraf, Hamdan Al-Jahdali, Abdul Hameed Al Qaseer, Anamarija Gjurovic, Houria Haouichat, Basheer Khassawneh, Bassam Mahboub, Roozbeh Naghshin, François Montestruc, Naser Behbehani
BACKGROUND: Low levels of asthma control are reported in many countries worldwide. Improved knowledge of asthma control in the Middle East and Africa and predictive factors is needed to address this major public healthcare burden. OBJECTIVE: To assess the level of asthma control in patients attending a routine consultation for asthma in the Middle East and North Africa, and the relationship between level of control and patient and disease characteristics, adherence, and quality of life (QoL)...
May 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29720350/hospitalizations-for-asthma-exacerbation-in-chilean-children-a-multicenter-observational-study
#20
A M Herrera, P Brand, G Cavada, A Koppmann, M Rivas, J Mackenney, H Sepúlveda, M E Wevar, L Cruzat, S Soto, M A Pérez, A León, I Contreras, C Alvarez, B Walker, C Flores, V Lezana, C Garrido, M E Herrera, A Rojas, C Andrades, E Chala, R A Martínez, M Vega, J A Perillán, H Seguel, I Przybyzsweski
BACKGROUND: Asthma hospitalization rates in Chilean children have increased in the last 14 years, but little is known about the factors associated with this. OBJECTIVE: Describe clinical characteristics of children hospitalized for asthma exacerbation. METHODS: Observational prospective cohort study in 14 hospitals. Over a one-year period, children five years of age or older hospitalized with asthma exacerbation were eligible for inclusion...
April 29, 2018: Allergologia et Immunopathologia
keyword
keyword
81415
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"